First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Works matching AU Boisserie, Frederic
Results: 2
1
2
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 5, p. 548, doi. 10.1159/000537966
- By:
- Publication type:
- Article